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Abstract
Epstein-Barr virus (EBV) is a highly successful herpesvirus, colonizing more than 90% of the adult human population
worldwide, although it is also associated with various malignant diseases. Primary infection is usually clinically
silent, and subsequent establishment of latency in the memory B lymphocyte compartment allows persistence of
the virus in the infected host for life. EBV is so markedly B-lymphotropic when exposed to human lymphocytes in
vitro that the association of EBV with rare but distinct types of T and NK cell lymphoproliferations was quite
unexpected. Whilst relatively rare, these EBV-associated T and NK lymphoproliferations can be therapeutically
challenging and prognosis for the majority of patients is dismal. In this review, we summarize the current
knowledge on the role of EBV in the pathogenesis of these tumours, and the implications for treatment.
Introduction
Primary infection with EBV usually occurs via salivary
transmission. It is unclear whether the initial infection
occurs in epithelial cells or in B cells in mucosal tissues,
but it is infection of B cells that enables life-long persis-
tence of the virus as a largely asymptomatic infection
[1]. EBV enters resting B cells via the CD21 receptor
and MHC-II co-receptor surface molecules [2-4]. In
vitro, infection of B cells results in expression of a lim-
ited subset of genes which cooperate to induce cell pro-
liferation and transformation into lymphoblastoid cell
lines; these genes include six nuclear antigens (EBNA1,
EBNA2, EBNA3A, EBNA3B, EBNA3C and EBNA-LP)
and three membrane proteins (LMP1, LMP2A and
LMP2B) which are expressedt o g e t h e rw i t ha b u n d a n t
non-coding RNAs (EBER1 and EBER2) and several
micro-RNAs [5]. In vivo, EBV-infected B cells may
undergo limited expansion induced by the transforma-
tion-associated viral genes, but thereafter the infected B
cells revert to a latent state in the circulating memory B
cell pool to evade virus-specific immune T cell
responses [1,6]. Normal plasmacytoid differentiation of
virus-carrying B cells in lymphoid tissues may lead to
reactivation of virus into lytic replication [7], which
involves expression of around 80 viral genes and the
production of new infectious virions [8]. Released vir-
ions may in turn infect epithelial cells in the oropharynx
[9-12], facilitating further virus production in differen-
tiating epithelium and release into the oropharynx [13]
for horizontal transmission to new hosts.
From this understanding of the normal life cycle of
EBV, it is possible to envisage how genetic accidents
might give rise to EBV-associated malignancies of B cell
or epithelial cell origin [1]. What this classical model of
the EBV life-cycle does not explain is how EBV-asso-
ciated diseases of T or NK cells might arise. Indeed, as
mature T and NK cells do not express CD21 it is
unclear how these cells become infected in the first
place. However, EBV-carrying T and NK cells can
undoubtedly result in severe clinical syndromes.
EBV infection of T or NK cells in vivo
EBV is not detected in NK or T cells in the blood of
healthy carriers, but may be detected at extremely low
frequency in tonsillar NK or T cells [14], notably in
some patients with infectious mononucleosis (IM), a
self-limiting clinical manifestation of primary EBV infec-
tion [1]. Infection of NK or T cells is probably an ineffi-
cient and rare event, consistent with the lack of CD21
expression on these cells. Nevertheless, a number of
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been identified, and are now recognised to comprise a
heterogeneous spectrum of diseases, affecting humans
through all stages of life and conferring considerable
morbidity and mortality. The fundamental unifying fea-
ture of such illnesses appears to be the clonal expansion
of EBV-infected T or NK cells, although the specific
viral and host factors initiating and potentiating the dis-
ease processes remain largely unresolved. Furthermore it
remains quite unclear why infection of similar or identi-
cal cell types is associated with such a diverse spectrum
of clinical illnesses, occurring both in previously EBV-
naive and ostensibly EBV-immune individuals. The clini-
cal, pathological and biological features of the individual
diseases are detailed below.
Chronic Active EBV
In 1948, Isaacs described a cohort of patients with fati-
gue, fever, splenomegaly and small volume lymphadeno-
pathy persisting for 3 months to over 4 years after an
initial episode of clinically-defined IM [15]. A subse-
quent study of acute IM patients noted that although
most patients had an unremarkable clinical course, a
subset of patients experienced protracted symptomatol-
o g yo v e rp e r i o d so f4t o2 8m o n t h s ;t h e s ep a t i e n t s
tended to have unusually high and persistent titres of
antibodies to EBV capsid antigen (VCA) and a delayed
antibody responses to early antigen (EA) [16].
There are now numerous reports of patients with clin-
ical syndromes consistent with ‘chronic symptomatic
EBV infection’, although terminological inconsistencies
have caused some confusion. The term chronic active
Epstein-Barr virus (CAEBV) disease describes patients
with a systemic EBV-positive lymphoproliferative disease
characterised by fever, lymphadenopathy and splenome-
galy developing after primary EBV infection in patients
without known immunodeficiency [17]. Suggested diag-
nostic guidelines required persistence of symptoms for
at least 6 months associated with high IgG antibody
titres to VCA and EA. Absent or low titres of antibodies
to EBV nuclear antigen-1 (EBNA1) are also characteris-
tic of patients with chronic symptoms following proven
IM [17,18]. This definition [17] arose from observations
on affected children from the Western hemisphere and
was proposed to result from progressive EBV infection
of B cells, although this was not formally proven.
Infection of T and NK cells in CAEBV
The first evidence of an association of CAEBV with
infection of non-B cells arose from a detailed clinico-
pathological study of a young child with clinical and ser-
ological evidence of CAEBV [19]. EBNA
+ cells were
detected in blood, bone marrow and lymph node and,
unexpectedly, clonal EBV genomes were identified in
peripheral blood CD4
+ T lymphocytes. There followed a
series of reports, predominantly from Japan and East
Asia, demonstrating the striking pathological feature of
EBV-infected T or NK cells in the blood or tissue of
affected patients [20-26]. Importantly, Southern blot
analysis of viral terminal repeats consistently demon-
strated clonal or oligoclonal EBV genomes [20-25],
implicating the virus in the early stages of disease
pathogenesis.
The application of quantitative PCR for EBV genome
load in peripheral blood and tissue biopsies [27] has
provided a more sensitive diagnostic parameter than
EBV serology data, which can be normal in a minority
of patients with clear clinicopathological evidence of
CAEBV [25]. CAEBV patients assessed prior to therapy
have viral load values in the order of 10
3-10
7 genomes/
10
6 PBMC [25,28] and 10
2-10
6 copies per ml of plasma
[29-31]. There is evidence to suggest that disease sever-
ity correlates with higher viral loads [25].
I n t e r e s t i n g l y ,av e r yr e c e n ts t u d yo fC A E B Vc a s e si n
US patients (of predominantly non-Asian descent)
found that, in contrast to the East Asian data, B cells
were the major target of EBV, with clonality demon-
strable in all cases. Cases with T and NK disease did
occur, albeit less frequently [32]. Reliable estimates of
the incidence of CAEBV cannot be made from existing
published data, but the indications are that it is rare in
East Asia and even rarer in the West [33].
Clinical features, prognosis and therapy for CAEBV
A detailed Japanese study of 30 CAEBV cases [25], fol-
lowed by a nationwide survey that captured data on 82
patients in the period 1990-2001 [28], included elevated
EBV DNA load in blood or tissue as a diagnostic criter-
ion alongside the increasingly recognised clinical fea-
tures, including: fever, hepatitis, lymphadenopathy,
hepatosplenomegaly, pancytopenia, uveitis, interstitial
pneumonia, hydroa vacciniforme [34], or hypersensitivity
to mosquito bites [22]. Interestingly, patients in these
analyses could be delineated into two groups according
to whether T cells or NK cells were the predominant
EBV-harbouring cell, and each respective group
appeared to exhibit different clinical features and prog-
nosis. T cell-type infection was characterised by fever
and high titres of EBV-specific antibodies, whereas
patients with NK cell-type infection exhibited hypersen-
sitivity to mosquito bites and high titres of IgE as distin-
guishing features. Patients with T cell-type infection
appeared to have significantly poorer outcomes
[25,28,35]. For the whole study group of 82 CAEBV
patients, predominantly children, overall survival was
58% at 10 years [28].
The optimal treatment for CAEBV remains unclear
but given the generally poor outcomes following
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therapeutic approach comprising sequential immunomo-
dulation, cytotoxic chemotherapy and allogeneic hema-
topoietic SCT (allo-HSCT) has been studied [36]. In a
small cohort of 18 patients receiving such a protocol,
the 3-year overall survival was 95.0%. Importantly, a pla-
teau in the survival curve is evident, suggesting the
potential of allo-HSCT to achieve long-term disease-free
survival for patients with severe CAEBV.
The recent retrospective US study described similar
clinical features, albeit in an older cohort (mean age 19
years) and comparable survival data, with no apparent
difference in outcome between those with T or NK dis-
ease and B cell CAEBV cases. Allo-HSCT appeared to
provide a curative option for some patients, sometimes
in the context of refractory disease [32].
EBV-associated Haemophagocytic
Lymphohistiocytosis
The earliest description of a distinct clinical syndrome
associated with histological evidence of erythrophagocy-
tosis (see Figure 1) was reported in 1939 by two Oxford
Pathologists [37]. A detailed description of four fatal
cases, termed ‘histiocytic medullary histiocytosis’ was
summarised as follows. “These cases illustrate what we
have come to regard as the typical clinical course of the
disease: fever, wasting and generalised lymphadenopathy
are associated with splenic and hepatic enlargement and
in the final stages jaundice, purpura and anaemia with
profound leukopenia may occur. Post mortem examina-
tion shows a systematised hyperplasia of histiocytes
actively engaged in phagocytosis of erythrocytes”.T h e s e
prescient observations remain central features of inter-
nationally agreed diagnostic criteria of the present-day
clinicopathological syndrome now termed Haemophago-
cytic Lymphohistiocytosis (HLH) [38].
Similar clinicopathological entities have been reported
under various terminologies, including familial haemo-
phagocytic reticulosis [39], familial erythrophagocytic
lymphohisticytosis [40], histiocytic medullary reticulosis
[41] and malignant histiocytosis [42]. These reports
included seemingly inherited syndromes and some attri-
butable to, or associated with, malignancy. One Japanese
survey estimated that the incidence of HLH was less
than 1 case/million population/year [43], although the
diagnostic challenges and the nature of this study sug-
gest that this may be an underestimate. The incidence
of HLH in the Japan is likely to be higher than that in
Western countries.
EBV as an aetiological agent of a subset of HLH
A possible link with viral infection was highlighted from
a study of HLH in a group including patients immuno-
suppressed following renal transplantation [44]. Evi-
dence of active viral infection, predominantly
herpesviruses, was obtained in the majority of cases.
This entity was termed virus-associated haemophagocy-
tic syndrome (VAHS). Two cases with high IgM titres
to EBV, suggested a role for EBV in disease pathogen-
esis in some cases of HLH [44]. The apparent associa-
tion with primary EBV infection prompted a detailed
analysis of 52 cases of fatal IM in which, following a
initially typical presentation of IM, severe pancytopenia
developed together with bone marrow evidence of infil-
tration by lymphoid cells, cellular necrosis and marked
histiocytic haemophagocytosis. The median survival
time of these patients was six weeks, in whom an
Epstein-Barr virus-associated haemophagocytic syn-
drome was strongly implicated in the cause of death
[45]. It is now clear that EBV is the most frequent cause
of acquired HLH in the immunocompetent host
[43,46,47].
A major breakthrough implicating EBV as a key
aetiological agent in HLH, was the identification of
viral genomes within T lymphocytes in tissue biopsies
of affected individuals [48-50]. Monoclonality of EBV
by Southern blot analyses together with clonal rearran-
gements of T-cell receptor gene sequences provided
evidence of clonal proliferation of a T cell infected
with EBV. This was supported by in situ hybridisation
analyses at the single-cell level, showing EBER-specific
signals exclusively within a CD45RO
+ TCRb
+popula-
tion; importantly, EBERs were not detectable in B cells
or macrophages [51]. Notably, some reports indicated
that EBV
+T cell lymphoma could arise from or co-
exist with HLH [48], although clear delineation
between the two entities is not always straightforward
[52-54].
Figure 1 Haemophagocytosis in the bone marrow.A
photomicrograph of a bone marrow aspirate (original magnification
x200) from a UK patient, showing an area of marked macrophage
activity and haemophagocytosis. Lipid-laden macrophages are seen
to engulf haemopoeitic precursors.
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CD3
+ T cells, most often the CD8
+ subset, both in tis-
sue biopsies [21,49,51,52,55-57] and circulating lympho-
cytes [26,58], are the dominant infected population in
EBV-HLH. However, unequivocal infection of NK cells
has also been observed, and may even be the dominant
infected cell type in some patients [59].
Epidemiology and risk factors for HLH
The majority of cases of EBV-HLH occur in the context
of primary infection [45,49,50,60] in children and ado-
lescents [61-63]. Adult cases of HLH are rare and are
more frequently attributable to malignancy, particularly
lymphoma [43,64]. In common with other entities
within the spectrum of EBV
+ T and NK lymphoproli-
f e r a t i o n s ,t h el i t e r a t u r ei sd o m i n a t e db yam a j o r i t yo f
EBV-HLH cases reported by study groups in East Asia
[62]. However, instances in patients of European [49,58],
Middle Eastern [54], North American and Hispanic [52]
ethnicities have been described. Notwithstanding the
fact that inherited immunodeficiencies [65-69] strongly
predispose to HLH, and that the original description of
VAHS arose in a largely immunocompromised patient
group [44], most patients presenting with EBV-HLH
have no clinical history of immunodeficiency.
Pathophysiology of HLH
An in vivo model of HLH [70] described the emergence
of erythrocyte and platelet antibodies at the time of
peak viral load. This appearance of antibody-coated ery-
throcytes anteceded erythrophagocytosis in tissues and
heralded the onset of the full clinical syndrome. This
phagocytosis was shown to be specifically mediated by
Fc-mediated macrophage activation and results in the
observed cytopenias.
The clinical manifestations of HLH are, at least in
part, a result of a dramatically dysregulated inflamma-
tory response due to release of pro-inflammatory cyto-
kines including IFN-g,T N F - a,I L - 6 ,I L - 1 0a n dM - C S F
[71]. These mediators are secreted by activated T-lym-
phocytes and infiltrating histiocytes, which can instigate
tissue necrosis and organ dysfunction. Inflammatory
cytokines are also responsible for the haematological
and biochemical manifestations such as cytopenias, coa-
gulopathy and elevated triglycerides [65]. Serum Fas
ligand (a membrane protein expressed by cytotoxic T
and NK cells) has also been noted to be elevated in
patients with HLH [72] and may explain features such
as liver dysfunction.
Impairment of the cytotoxic function of NK and T
cells seems to be a common denominator across both
inherited and acquired HLH syndromes [47,73],
although the mechanisms leading to cytolytic defects in
immunocompetent patients with EBV-HLH are not
clear. Elevated levels of cytokines such as IL-12 have
been shown to impact on NK function [74]. The appar-
ent geographical disparities in the incidence of EBV-
HLH may suggest a hitherto unidentified genetic sus-
ceptibility resulting in a dysfunctional immune response
to infected cells.
Prognosis and therapy of EBV-HLH
The aims of therapy are to suppress the augmented
inflammatory response with immunosuppressive/immu-
nomodulatory agents, support and restore organ func-
tion, and eliminate EBV-harbouring cells with cytotoxic
drugs [75-81]. The best clinical evidence has followed
from studies based on the international HLH-94 proto-
col [38,82,83], incorporating etoposide, dexamethasone
and Cyclosporin A [82]. In the case of refractory disease
[63], or those with familial defects [84], allo-HSCT can
result in long-term disease-free survival.
An analysis of 78 children with EBV-HLH treated with
an etoposide-based regimen showed 75.6% of patients
were alive and well after a median follow-up of 4 years,
indicating the effectiveness of similar immuno-che-
motherapy protocols as used for familial disease [38,82].
The prognosis and outcome of adult patients with EBV-
HLH has been less well studied. The available published
data [52,54,64,85] suggest a more adverse prognosis for
adults than children with EBV-HLH, although a higher
incidence of co-existing lymphoma in adults, and lack of
treatment uniformity may confound these data.
Extra-nodal NK/T-cell lymphoma, nasal type
Extra-nodal NK/T-cell lymphoma (ENKTL) is a rela-
tively recently characterised clinicopathological entity,
being formally incorporated into the WHO classification
of haematopoietic and lymphoid tumours in 1999 [86].
However, this entity was probably recognised over a
century earlier in 1897 by McBride, who described a
patient in whom an ulcer developed on the left lateral
surface of the nose that within a year, at the time of
death, had extended to both cheeks causing extensive
tissue damage to the nose and upper lip [87]. A subse-
quent report in 1921 [88] described two patients with
destructive nasal lesions, in whom syphilis was excluded
as a diagnosis and no infectious organism could be iden-
tified. Further clinical and histological accounts of such
a disease accumulated over the following decades
[89-95]. Various terminologies for ENKTL have been
used, including: lethal midline granuloma, rhinitis gang-
renosa progressiva, polymorphic reticulosis, and malig-
nant midline reticulosis.
Phenotype and genotype of ENKTL
As t u d yb yI s h i iet al was the first to demonstrate that
the malignant cells in ENKTL reacted with anti-sera
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rate analysis found evidence of rearranged T cell recep-
tor (TCR) genes in ENKTL tissue indicative of a clonal
T-cell proliferation [97]. The apparent T-cell origin of
this lymphoma was corroborated by further pathological
studies in East Asia [98,99] and the United States [100].
However, the development of antibodies against the
CD56 antigen questioned the T cell phenotype of the
malignant cells [101-104]. It is now recognised that the
majority of ENKTL tumours are of NK cell origin, with
germline T cell receptor gene configurations
[102,105-110]. The reactivity of polyclonal anti-CD3
antibodies with the cytoplasmic subunit (ε-chain) of the
CD3 molecule in formalin-fixed tissues is the likely
explanation for the original phenotypic interpretation
[111-114].
The characteristic phenotype of ENKTL is now under-
stood to comprise CD2
+,C D 5 6
+, surface CD3
- (as
demonstrated on fresh/frozen tissue) and cytoplasmic
CD3ε
+ (as demonstrated on FFPE tissues). The largest
clinicopathological study of ENKTL since its incorpora-
tion into the WHO classification [86,115], analysed 136
cases of ENKTL and confirmed the expression of CD56
and cytotoxic markers (TIA-1 and granzyme) in a
majority of cases, but also identified a minority of
tumours (14%) with a CD8
+ phenotype. Rearranged T
cell receptor genes were found in approximately one-
third of 52 cases tested [116].
Association of ENKTL with EBV
The first compelling evidence implicating EBV in the
development of T and NK lymphomas arose from a
report describing 3 patients with clinical and serological
features suggesting pre-existing CAEBV, who subse-
quently developed fatal T cell lymphoma containing clo-
nal EBV [117]. Subsequent studies identified EBV
genomes and/or EBERs within the tumour cells of both
nasal and extra-nasal T and NK lymphomas arising in
children and adults [103,107,109,118,119]. The associa-
tion with EBV was observed to be most robust in extra-
nodal lymphomas and those arising in the nasopharynx
[120]. The clonal and episomal form of the virus in the
tumour cells [121,122], together with the expression of
EBV-encoded transcripts and proteins [21,121-124], sug-
gested a causative role for the virus in disease pathogen-
esis. The association of ENKTL with EBV is invariable,
irrespective of geographical origin [116]. Indeed, demon-
stration of the virus in the malignant cells is virtually a
requisite for diagnosis [115].
Epidemiology and clinical features of ENKTL
ENKTL is an aggressive malignancy with a unique geo-
graphical distribution; rare in Western countries and
more frequently encountered in East Asia and Central/
South America [116,125-131]. Robust data are lacking
for the incidence of ENKTL as defined by WHO diag-
nostic criteria, and this is currently being addressed by
the ongoing International T cell project directed by
Massimo Federico, Modena, Italy (ClinicalTrials.gov
Identifier: NCT00705809). Nevertheless, large epidemio-
logical studies of consecutive NHL cases in China [127]
and Korea [126] have shown that whilst mature T and
NK neoplasms (of all subtypes) comprise approximately
30% NHL, ENKTL accounts for approximately 4-6% of
incident NHL cases. By contrast, the best estimate of
incidence in Europe and the United States is that
ENKTL represents 4% of all NK and T cell lymphoma
subtypes [116], which equates to approximately 0.5% of
all NHLs [132]. From these data it can be estimated that
the incidence of ENKTL may be less than 0.5 cases/mil-
lion population/year in Western countries and in the
region of 2-4 cases/million population/year in some
Eastern regions.
Patients with ENKTL are usually immunocompetent.
The median age of presentation is 45-50 years with a
male: female ratio of 2-3:1 [116,126,133-135]. However,
it should be emphasised that demographic data on this
disease (relating to incidence, age/sex distribution and
patient ethnicity) is not well characterised outside East
Asia.
ENKTL commonly affects the upper aero-digestive
tract (characteristically the nasal cavity), though extra-
nasal disease (e.g. skin, gastrointestinal tract, testis) can
account for one quarter of cases [116]. Primary lymph
node involvement is rare. Bone marrow involvement at
diagnosis, as determined by conventional immunohisto-
chemistry, occurs in a minority (6-14%) of cases
[116,136] although this may be an underestimate [137].
Clinical presentation is typically referable to local symp-
toms from a nasal mass, including obstructive symptoms
and bleeding. Hoarseness of voice, dysphagia, proptosis,
ophthalmoplegia and dysphonia can also occur accord-
ing to the extent of local tumour invasion [138]. Poorer
prognosis is conferred by local invasiveness, elevated
serum lactate dehydrogenase, advanced stage disease
and the presence of B symptoms [116,136].
Therapy for ENKTL
ENKTL is clinically aggressive, displaying inherent resis-
tance to anthracycline-based chemotherapy regimens
such as CHOP [139], adopted empirically from B cell
lymphoma studies. The outcome of extra-nasal and
advanced stage disease is extremely poor [116,136,138].
However, the tumours are usually sensitive to radiation
therapy which, when given at relatively high doses [140],
is the mainstay of front-line therapy for localised disease
[141]. However, in spite of high rates of initial response
following involved-field radiotherapy, up to 50% of those
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within a year of completing first-line therapy
[138,141-143]. Recently published data from early phase
clinical trials examining concurrent chemo-radiotherapy
in localised ENKTL [144,145], and chemotherapy com-
bined with L-asparaginase for relapsed/refractory
ENKTL are encouraging [146-149], but remain to be
tested in randomised phase III clinical studies. Never-
theless, despite signs of therapeutic progress, an extre-
mely poor outcome is anticipated for the majority of
patients with this disease. Data from the international T
cell project study [116], showed a median overall survi-
val of 7.8 months for patients with ENKTL, representing
the poorest survival of all T cell lymphoma subtypes
examined [150].
Attempts to improve outcome in ENKTL have
included studies of high-dose chemotherapy (HDT) with
autologous stem cell transplantation (ASCT), primarily
undertaken in East Asia. The majority of published data
are based on retrospective analyses of relatively small
cohorts [151-153]. A pooled analysis of 47 patients from
3 studies suggested a survival advantage for those
undergoing ASCT, althought h es u r v i v a lb e n e f i t
appeared small and larger collaborative studies are
necessary to demonstrate unequivocal benefit for this
approach.
The notion of harnessing a graft-versus-lymphoma
effect against malignancies inherently resistant to con-
ventional therapies is attractive and clearly has a role for
some patients with more common subtypes of T cell
lymphomas [154,155]. The invariable presence of EBV
in the tumour cells of ENKTL, expressing the viral anti-
gens EBNA1, LMP1 and LMP2, provides additional allo-
reactive T cell targets. Moreover, initial in vivo studies
have adoptively transferred autologous, ex-vivo-stimu-
lated, LMP2-specific cytotoxic T lymphocytes to patients
with ENKTL with encouraging results [156,157].
The role of allogeneic HSCT for patients with ENKTL
remains unclear. Data from two small series [153,158]
(comprising six and twenty-two patients) suggest that a
proportion of patients with relapsed and refractory dis-
ease can achieve long-term disease-free survival, pre-
sumably mediated through a graft-versus lymphoma
effect.
Aggressive NK leukaemia
The first distinct report of an aggressive NK cell leukae-
m i a( A N K L )i na na d u l td e s c r i b e di na7 1y e a ro l d
white man from the United States [159], although the
majority of subsequent reports from East Asia have
occurred in younger individuals [160]. A cell line estab-
lished from the first case retained morphological, immu-
nologic, and functional characteristics of NK cells [159].
Further reports of clinically aggressive leukaemias
displaying neither a B nor T cell phenotype
[102,159,161,162] suggested that such malignancies can
arise from non-T cell large granular lymphocytes, or NK
cells. The WHO subsequently recognised this aggressive
leukaemia as a distinct clinicopathological entity and
ANKL was separately incorporated into the lymphoid
tumour classification [86].
Association of EBV with ANKL
In the initial reports of ANKL, studies for EBV were not
always performed, although it is now recognised that >
90% of ANKL cases harbour clonal, episomal EBV
[23,163,164].
Clinical features, prognosis and therapy for ANKL
ANKL is extremely rare, with approximately 100 pub-
lished cases worldwide [165]. The disease typically
affects young to middle age patients (mean age approxi-
mately 40 years), with a slight male predominance.
Patients with ANKL are almost always systemically
unwell at presentation, usually with a high fever and
constitutional symptoms such as sweats and weight loss.
A leukaemic picture is invariably found, associated with
prominent thrombocytopenia and variable degrees of
anaemia and neutropenia [165]. Cytogenetic abnormal-
ities are seen in at least two-thirds of cases and are
often complex [160,165].
Most cases of ANKL pursue an inexorable clinical
course, typically displaying resistance to cytotoxic thera-
pies. Complications such as coagulopathy, haemophago-
cytic syndrome and multi-organ failure are not
uncommon. In spite of treatment with intensive che-
motherapy, mortality from ANKL is virtually inevitable
with a median survival of less than 2 months
[160,163,166-168]. Even for the minority of patients who
experience an initial remission following an anthracy-
cline-based regimen, relapse occurs invariably and
attempts to improve outcome by the use of allogeneic
bone marrow transplantation [169] have not proved
widely successful [168].
Differences between ANKL and ENKTL
ANKL shares many features with extra-nodal NK/T
lymphoma, including: cytological features, an almost
identical immunophenotype [108] (CD2
+,C D 3 ε
+ and
CD56
+) although CD16 is thought to be more frequently
expressed on ANKL than ENKTL [168,170], and a lack
TCR gene rearrangements [108,165]. As with ENKTL,
ANKL is also seen with increased incidence in East
Asia. In the vast majority of cases, distinct clinical fea-
tures allow these diseases to be clearly delineated,
although some patients with ENKTL may progress to an
aggressive, systemic disease akin to ANKL [171,172].
However, comparative genomic array studies support
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[173].
EBV gene expression in T and NK
lymphoproliferations
A key element to understanding the possible role of
EBV in associated disease is knowledge of the pattern of
viral gene expression. As mentioned earlier, EBV is a
potent transforming agent for primary B cells in vitro,
where the establishment of lymphoblastoid cell lines
requires the cooperative functions of several so-called
‘latent genes’ [1]. The pattern of viral gene expression in
LCLs is commonly referred to as ‘Latency III’ [5,174]. In
vivo, Latency III may be observed in some EBV infected
tonsillar B cells in acute IM patients [14,175] or in
immunoblastic B lymphomas in iatrogenically immuno-
suppressed patients [176,177]. However, EBV-associated
malignancies are usually associated with more restricted
patterns of viral gene expression (Figure 2), because
other cellular genetic changes negate the requirement
for full Latency III expression and because expression of
viral antigens for initiating or maintaining cellular trans-
formation has to be balanced against the cost of antigen
exposure to immune-surveillance mechanisms.
The first EBV malignancy shown to express a more
restricted pattern of latent viral gene expression was
Burkitt’s lymphoma (BL), where the only viral protein to
be expressed is EBNA1 [178,179] which is essential for
the maintenance of the viral episome in dividing cells
[180-182]. These tumours also express the non-coding
EBERs [178] and several microRNAs derived from the
BART transcripts [183]. This pattern of gene expression
is commonly referred to as Latency I (Figure 2). Such a
restricted pattern of transformation-associated latent
genes is possible in BL as these tumours invariably carry
chromosome translocations resulting in deregulated
expression of the c-myc oncogene [1,184]. It has been
proposed that EBNA1, EBERs and BARTs might
cooperate with c-myc driven proliferation in maintaining
the malignant phenotype by contributing anti-apoptotic
and immune-modulating functions [184].
A third major type of latency in EBV-associated malig-
nancies is Latency-II, in which LMP1, LMP2A and
LMP2B proteins are expressed in addition to the
Latency I genes (Figure 2). These membrane proteins
are important modulators of cell signalling, conferring
strong protection against apoptotic signals [185,186] and
blocking terminal differentiation of infected cells
[187-190]. Prototypic examples of Latency II tumours
are nasopharyngeal carcinoma and Hodgkin’s lymphoma
[1].
Reverse Transcriptase Polymerase Chain Reaction
(RT-PCR) assays for EBV latent transcripts can be very
sensitive and, by taking advantage of the fact that all
latent protein mRNA are products of spliced primary
RNA transcripts [8], can be made highly specific and
eliminate the possibility of contamination of the assay
with viral DNA. In contrast to immunohistochemistry
and in situ hybridisation techniques, RT-PCR assays
only provide information at the population level within
a sample and heterogeneity within a tumour may there-
fore be missed. However, as EBNA1 is produced from
different promoters with different splice products in
Latency I or Latency II (Qp promoter) and Latency III
(Cp or Wp promoters), and expression of LMP1/2 can
distinguish between Latency II and Latency I, RT-PCR
can be a simple and sensitive method for distinguishing
the major forms of latency [5]. A caveat, however, is
that RT-PCR detects expression in the total population
which may contain heterogenous patterns of latency at
the single cell level.
It is important to recognise that the Latency I, II, III
nomenclature represents just three common snapshots
of gene expression over a spectrum ranging from
Latency 0 (no EBV antigen expression, as observed in
circulating memory B cells in healthy infected
Figure 2 Patterns of latent viral gene expression in EBV-associated tumours. Schematic illustrating major patterns of EBV gene expression
observed in different virus:host interactions; non-coding RNAs and micro-RNAs are indicated in green type, nuclear proteins in black type, and
membrane proteins in blue type. Latency 0, sometimes referred to as ‘in vivo latency, is the type of latency observed in non-dividing circulating
memory B cells of healthy carriers; it is possible that the majority of these cells express no viral genes at all, but that a minority may express
non-coding RNAs. Latency I was originally identified in Burkitt’ lymphoma, Latency II in nasopharyngeal carcinoma and Hodgkin’s lymphoma,
and Latency III in post-transplant lymphoproliferative disease.
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formed lymphoblastoid B cell lines. Some tumours may
not fall neatly into one of these patterns of latency; for
example, LMP1 is often poorly expressed or undetectable
in nasopharyngeal carcinomas which otherwise display a
Latency II phenotype. Furthermore, immunohistochem-
ical analysis may indicate heterogeneity of expression
within a single biopsy, but the pattern of latency is often
misleadingly described according the sum total of viral
gene products detected.
Against this background, what is known about the
pattern of viral gene expression in EBV-associated T
and NK cell diseases?
EBV gene expression in CAEBV
Analyses of EBV-encoded proteins in cell lines established
from patients with CAEBV [191,192], suggest a Latency II
pattern of viral gene expression. Studies examining viral
gene expression in ex-vivo lymphocytes from CAEBV
patients have been scarce. Iwata et al [193] recently
described a pattern of EBV latent antigen expression
including Qp-initiated EBNA1, LMP1, and LMP2; EBNA2
and lytic transcripts were absent. This pattern is indicative
of Latency II. Although this study used RNA extracted
from total PBMC, the virus in each case was confirmed to
be predominantly within the T or NK population. These
results were consistent with previous, non-quantitative
PCR studies on CAEBV PBMC ex-vivo [35,194].
EBV gene expression in HLH
The pattern of EBV gene expression in EBV-HLH
remains unclear. EBERs are frequently expressed [51].
However, whether EBV-HLH lymphoproliferations dis-
play a Latency II pattern of viral gene expression, in
keeping with the related T or NK disease CAEBV [195]
has not been adequately studied. One limited study ana-
lysed mRNA from splenic and peripheral blood mono-
nuclear cells in 3 patients with EBV-HLH and found
expression of EBERs, Wp/Cp- and Qp-initiated EBNA1,
together with EBNA2, LMP1 and LMP2A transcripts
[196]. This suggests alternate promoter usage in different
cell populations, most likely with a Latency III expression
in B cells, which limits interpretation of the data. In
another study [59] EBER transcripts were detected in the
absence of protein-coding transcripts, which is at odds
with the requirement for EBNA1 expression for mainte-
nance of the viral genome in dividing cells. Further stu-
dies, preferably including analysis of expression at the
single cell level, are required to ascertain the pattern of
viral gene expression typically exhibited in EBV-HLH.
EBV gene expression in ENKTL
Initial analyses of six cases of ENKTL, confirming the
presence of the virus within the malignant cells [121],
also found numerous LMP1 positive cells by immuno-
histochemical staining in four of six cases. A more com-
prehensive follow-up study analysed 23 cases of ENKTL
[123]. Immunostaining for LMP1 revealed heteroge-
neous membrane positivity in a sub-population of EBER
+ cells in 15 of 23 cases. Of note, both cases of extra-
nasal tumours analysed by Chiang et al [123] were
LMP1 negative and, importantly, none of the 23 cases
expressed EBNA-2 or BZLF1 protein, which is consis-
tent with Latency II or Latency I and no activation of
lytic cycle. Further characterisation of RNA transcripts
by non-quantitative end-point RT-PCR revealed expres-
sion of BARTs (precursor transcripts for BART miR-
NAs) in the majority of cases, whilst EBNA1 transcripts
were detected in 15/23 cases and confirmed to be Qp-
initiated. LMP1 transcripts were readily detected in all
cases, although LMP2A and LMP2B mRNAs were
absent or low in the majority of tumours.
These initial data have been broadly supported by sub-
sequent studies [21,122-124,197-200] suggesting that
ENKTL typically express a Latency II pattern of gene
expression, although both inter- and intra-tumour het-
erogeneity exists. In particular, LMP1 expression is vari-
able and heterogeneous at the single cell level in
ENKTL [123,200] (Figure 3), whereas LMP2A and
LMP2B mRNA levels appear low or absent in analysed
cases [123,197,199]. Recently, we demonstrated that
ENKTL express a hitherto unrecognised LMP2 tran-
script initiated from within the terminal repeats of the
EBV genome [191] that is predicted to encode a protein
identical to that from LMP2B transcripts. As the
LMP2B protein contains most of the immune T cell epi-
tope sequences identified to date for LMP2A/B, the
LMP2 product identified in ENKTL represents a viable
target for adoptive T cell immunotherapy. Although the
viral proteins expressed in ENKTL are not normally
immunodominant [1], ongoing work to amplify LMP1-
and LMP2-specific responses for adoptive transfer have
so far produced encouraging results for the treatment of
ENKTL [156,201].
EBV gene expression in ANKL
Due to the rarity of this disease and the often rapidly
fatal course, analyses of EBV gene expression in ANKL
have been scarce. However, one study from Shanghai
found that nine consecutive cases of EBER
+ ANKL were
LMP1 negative by immunostaining [165].
Unanswered questions in EBV-associated NK and
T lymphoproliferations
A fundamental unanswered question remains: how does
EBV infect NK or T cells? Although experimental infec-
tion of primary NK cells and NK cell lines has been
reported to be an efficient process [202] these results
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of observed NK and T cell infections in vivo, would favour
the interpretation that infection of these cells is a rare
event, but with potentially catastrophic clinical conse-
quences. Whilst the mechanisms of infection in vivo have
yet to be elucidated, two attractive possibilities remain to
be excluded. The first is via immunological synapses,
whereby conjugates between effector T cells or NK cells
and virus-harbouring target cells might in rare circum-
stances facilitate transfer of virus from the target cell to
the immune effector cell, akin to that demonstrated for
HIV [203,204]. The second mechanism might involve
infection of immature precursor cells. It has previously
been reported that immature thymocytes transiently
express CD21 and can be infected with EBV and whilst
the pattern of viral gene expression was not established,
EBV was found to synergise with IL-2 to induce prolifera-
tion of these cells [205]. Furthermore, as CD34
+,C D 3 8
-
stem cells can be differentiated in vitro to transiently
express CD21 prior to commitment to T or NK cell line-
age (CSL, unpublished observation), this raises the
intriguing possibility that infection of a precursor cell has
the potential to give rise to either or both NK cells and T
cells carrying the same monoclonal EBV episomes. This
latter point is relevant to cases of CAEBV and HLH where
both cell types may carry EBV in the same patient. Indeed,
one recent study on childhood T/NK lymphoproliferations
indicated that in some cases the same monoclonal EBV
might be present in different cell populations, although no
evidence of infection of CD34
+ stem cells was found [206].
A second question relates to the heterogeneity of EBV
gene expression both between patients and within the
same lesion, as is seen with LMP1 expression in
ENKTL. Heterogeneity within a lesion may represent
two different phenotypes of the same parental tumour.
Alternatively, it may reflect a dynamic process akin to
that reported in EBV-transformed lymphoblastoid B cell
lines, where LMP1 levels vary among individual cells
such that the difference between the highest and lowest
expressing cells may be as great as 100-1000 fold at any
given time, but within hours the minimally expressing
cells revert to higher levels of LMP1 [207,208]. Studies
on EBV
+ T and NK tumour cell lines suggest that
LMP1 expression in individual cells within a lesion may
be substantially affected by local concentrations of cyto-
kines and by interactions with other cell types [209,210].
Heterogeneity between tumours may also be important;
the lack of detectable LMP1 in two extranasal ENKTL
from one study [123], raises the possibility that addi-
tional cellular genetic aberrations may be driving a more
malignant tumour phenotype that no longer requires
expression of the LMP1 oncogene. In this context it is
notable that ANKLs appear not to express LMP1 [165].
Finally, the recent demonstration that ENKTLs express
a novel LMP2 transcript, putatively encoding an immuno
sub-dominant LMP2B protein, has implications for both
the pathogenesis and therapy of these tumours [191].
These tumours represent the first example of EBV-
infected cells naturally expressing LMP2B in the absence
of LMP2A. This is notable since the N-terminus of
LMP2A, which is lacking in LMP2B, is responsible for its
major signalling functions. LMP2B acts as a dominant-
negative modulator of LMP2A function [211,212]. This
dominant-negative property of LMP2B has hitherto been
regarded as its major function. However, its expression in
the absence of LMP2A in ENKTL tumours highlights the
potential of LMP2B to function independently [212,213].
As LMP2B is likely to contribute to the initiation or
potentiation of EBV-associated NK and T cell diseases,
characterisation of the independent functions of LMP2B
may identify novel targets for therapy.
Conclusions
The rarity of EBV-associated NK and T cell malignan-
cies, and the consequent difficulty in obtaining patients
Figure 3 Heterogeneous LMP1 expression within an ENKTL
tumour. Upper photomicrograph: EBER in-situ hybridisation on a 4
μm formalin-fixed, paraffin-embedded ENKTL tissue section (optical
magnification x200). Courtesy of Dr Simon O’Connor, Department of
Histopathology, Nottingham University Hospitals. Lower
photomicrograph: Immunohistochemical stain of a 4 μm formalin-
fixed, paraffin-embedded ENKTL tissue section using CS1-4 (anti-
LMP1) antibodies. The image was captured with a Nikon
CoolpixE995 digital camera, via a Nikon Eclipse E400 microscope
(optical magnification, ×400).
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Page 9 of 15and tissues for study, has meant that these diseases have
been less well-studied compared to their B and epithelial
cell counterparts. This is unfortunate since they are
clinically challenging and the prognosis for many
patients is dismal. The aim of this review was to draw
attention to the current state of knowledge of the clini-
cal and virological features of these diseases, and to
highlight some unanswered questions regarding the role
of EBV in the disease pathogenesis. Deciphering the pre-
cise contribution of EBV to these rare T and NK lym-
phoproliferations will require collaborative, translational
e f f o r t st os t u d ys u f f i c i e n tn u m b e r so fp a t i e n t sa n du l t i -
mately achieve meaningful therapeutic progress for
patients.
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